Gastric cancer: p-mTOR a more valuable prognostic marker than mTOR

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In gastric cancer (GC) phosphorylated mammalian target of rapamycin (p-mTOR) is a more valuable prognostic marker than mTOR.

Why this matters

  • Novel prognostic biomarker for GC urgently needed.

Key results

  • mTOR, p-mTOR, p70S6k, and p-p70S6K expression rates were 60.8%, 54.2%, 53.3%, and 53.3%, respectively.
  • mTOR and p70S6K overexpression were not significantly associated with clinical variables.
  • p-mTOR expression was significantly associated with differentiation (P<.01), depth of invasion (P<.01), lymph node metastasis (P=.04) and TNM stage (P=.02); p-p70S6K was associated with differentiation (P=.006), invasion depth (P<.001), and TNM stage (P=.02).
  • Differentiation, invasion depth, lymph node metastasis, and TNM stage were not related to OS (all P.05); p-mTOR and p-p70S6K expression were closely associated with OS (P=.006 and P<.001, respectively), but mTOR and p70S6K were not.
  • Meta-analysis revealed no relationship between mTOR overexpression and any clinicopathological variables; p-mTOR was correlated with depth of invasion and TNM stage (both P<.05), and overexpression associated with shorter survival (P<.001).

Study design

  • Expression of mT...